vs
博士伦健康（BHC）与Raymond James Financial（RJF）财务数据对比。点击上方公司名可切换其他公司
Raymond James Financial的季度营收约是博士伦健康的1.5倍（$4.2B vs $2.8B），Raymond James Financial净利率更高（13.5% vs -3.7%，领先17.2%），博士伦健康同比增速更快（9.3% vs 3.5%），博士伦健康自由现金流更多（$403.0M vs $-56.0M），过去两年博士伦健康的营收复合增速更高（14.0% vs 7.1%）
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
雷蒙德詹姆斯金融是美国跨国独立投资银行及金融服务机构，通过旗下子公司为个人、企业及市政主体提供多元金融服务，核心业务覆盖投资与财务规划、投资银行、资产管理等领域，总部位于美国佛罗里达州圣彼得堡。
BHC vs RJF — 直观对比
营收规模更大
RJF
是对方的1.5倍
$2.8B
营收增速更快
BHC
高出5.8%
3.5%
净利率更高
RJF
高出17.2%
-3.7%
自由现金流更多
BHC
多$459.0M
$-56.0M
两年增速更快
BHC
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $4.2B |
| 净利润 | $-103.0M | $563.0M |
| 毛利率 | — | — |
| 营业利润率 | 17.0% | — |
| 净利率 | -3.7% | 13.5% |
| 营收同比 | 9.3% | 3.5% |
| 净利润同比 | -205.1% | -6.2% |
| 每股收益（稀释后） | $-0.30 | $2.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHCRJF
| Q4 25 | $2.8B | $4.2B | ||
| Q3 25 | $2.7B | $4.2B | ||
| Q2 25 | $2.5B | $3.8B | ||
| Q1 25 | $2.3B | $3.8B | ||
| Q4 24 | $2.6B | $4.0B | ||
| Q3 24 | $2.5B | $4.0B | ||
| Q2 24 | $2.4B | $3.8B | ||
| Q1 24 | $2.2B | $3.6B |
净利润BHCRJF
| Q4 25 | $-103.0M | $563.0M | ||
| Q3 25 | $179.0M | $604.0M | ||
| Q2 25 | $148.0M | $436.0M | ||
| Q1 25 | $-58.0M | $495.0M | ||
| Q4 24 | $98.0M | $600.0M | ||
| Q3 24 | $-85.0M | $602.0M | ||
| Q2 24 | $10.0M | $492.0M | ||
| Q1 24 | $-64.0M | $476.0M |
营业利润率BHCRJF
| Q4 25 | 17.0% | — | ||
| Q3 25 | 23.1% | — | ||
| Q2 25 | 17.5% | 14.7% | ||
| Q1 25 | 12.2% | 17.5% | ||
| Q4 24 | 21.8% | 18.6% | ||
| Q3 24 | 12.7% | — | ||
| Q2 24 | 16.2% | 17.1% | ||
| Q1 24 | 13.1% | 16.7% |
净利率BHCRJF
| Q4 25 | -3.7% | 13.5% | ||
| Q3 25 | 6.7% | 14.4% | ||
| Q2 25 | 5.8% | 11.3% | ||
| Q1 25 | -2.6% | 12.9% | ||
| Q4 24 | 3.8% | 14.9% | ||
| Q3 24 | -3.4% | 15.0% | ||
| Q2 24 | 0.4% | 13.1% | ||
| Q1 24 | -3.0% | 13.1% |
每股收益（稀释后）BHCRJF
| Q4 25 | $-0.30 | $2.79 | ||
| Q3 25 | $0.48 | $2.96 | ||
| Q2 25 | $0.40 | $2.12 | ||
| Q1 25 | $-0.16 | $2.36 | ||
| Q4 24 | $0.24 | $2.86 | ||
| Q3 24 | $-0.23 | $2.85 | ||
| Q2 24 | $0.03 | $2.31 | ||
| Q1 24 | $-0.17 | $2.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $9.9B |
| 总债务越低越好 | $20.8B | — |
| 股东权益账面价值 | $-554.0M | $12.6B |
| 总资产 | $26.4B | $88.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BHCRJF
| Q4 25 | $1.3B | $9.9B | ||
| Q3 25 | $1.3B | $11.4B | ||
| Q2 25 | $1.7B | $9.2B | ||
| Q1 25 | $1.1B | $9.7B | ||
| Q4 24 | $1.2B | $10.0B | ||
| Q3 24 | $719.0M | $11.0B | ||
| Q2 24 | $595.0M | $9.1B | ||
| Q1 24 | $733.0M | $10.0B |
总债务BHCRJF
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | — | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | — | ||
| Q1 24 | $22.1B | — |
股东权益BHCRJF
| Q4 25 | $-554.0M | $12.6B | ||
| Q3 25 | $-565.0M | $12.5B | ||
| Q2 25 | $-764.0M | $12.3B | ||
| Q1 25 | $-1.2B | $12.2B | ||
| Q4 24 | $-1.3B | $11.9B | ||
| Q3 24 | $-1.2B | $11.7B | ||
| Q2 24 | $-1.2B | $11.2B | ||
| Q1 24 | $-1.1B | $11.0B |
总资产BHCRJF
| Q4 25 | $26.4B | $88.8B | ||
| Q3 25 | $26.8B | $88.2B | ||
| Q2 25 | $27.3B | $84.8B | ||
| Q1 25 | $26.4B | $83.1B | ||
| Q4 24 | $26.5B | $82.3B | ||
| Q3 24 | $26.5B | $83.0B | ||
| Q2 24 | $26.5B | $80.6B | ||
| Q1 24 | $26.9B | $81.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $495.0M | $-10.0M |
| 自由现金流经营现金流 - 资本支出 | $403.0M | $-56.0M |
| 自由现金流率自由现金流/营收 | 14.4% | -1.3% |
| 资本支出强度资本支出/营收 | 3.3% | 1.1% |
| 现金转化率经营现金流/净利润 | — | -0.02× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $1.4B |
8季度趋势，按日历期对齐
经营现金流BHCRJF
| Q4 25 | $495.0M | $-10.0M | ||
| Q3 25 | $405.0M | $796.0M | ||
| Q2 25 | $289.0M | $691.0M | ||
| Q1 25 | $211.0M | $117.0M | ||
| Q4 24 | $601.0M | $830.0M | ||
| Q3 24 | $405.0M | $510.0M | ||
| Q2 24 | $380.0M | $711.0M | ||
| Q1 24 | $211.0M | $391.0M |
自由现金流BHCRJF
| Q4 25 | $403.0M | $-56.0M | ||
| Q3 25 | $314.0M | $752.0M | ||
| Q2 25 | $190.0M | $634.0M | ||
| Q1 25 | $96.0M | $71.0M | ||
| Q4 24 | $495.0M | $789.0M | ||
| Q3 24 | $334.0M | $460.0M | ||
| Q2 24 | $302.0M | $655.0M | ||
| Q1 24 | $129.0M | $342.0M |
自由现金流率BHCRJF
| Q4 25 | 14.4% | -1.3% | ||
| Q3 25 | 11.7% | 17.9% | ||
| Q2 25 | 7.5% | 16.5% | ||
| Q1 25 | 4.2% | 1.8% | ||
| Q4 24 | 19.3% | 19.6% | ||
| Q3 24 | 13.3% | 11.5% | ||
| Q2 24 | 12.6% | 17.4% | ||
| Q1 24 | 6.0% | 9.4% |
资本支出强度BHCRJF
| Q4 25 | 3.3% | 1.1% | ||
| Q3 25 | 3.4% | 1.1% | ||
| Q2 25 | 3.9% | 1.5% | ||
| Q1 25 | 5.1% | 1.2% | ||
| Q4 24 | 4.1% | 1.0% | ||
| Q3 24 | 2.8% | 1.2% | ||
| Q2 24 | 3.2% | 1.5% | ||
| Q1 24 | 3.8% | 1.3% |
现金转化率BHCRJF
| Q4 25 | — | -0.02× | ||
| Q3 25 | 2.26× | 1.32× | ||
| Q2 25 | 1.95× | 1.58× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | 6.13× | 1.38× | ||
| Q3 24 | — | 0.85× | ||
| Q2 24 | 38.00× | 1.45× | ||
| Q1 24 | — | 0.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
RJF
暂无分部数据
